Stem cell therapy

Osteoarthritis
Intravenous infusion of autologous MSCs has shown positive results in osteoarthritis by reducing joint pain, improving mobility, and decreasing inflammation. Patients often experience improved cartilage preservation and less joint stiffness. The mechanisms include immunomodulation through secretion of anti-inflammatory cytokines, paracrine effects stimulating cartilage repair, and inhibition of catabolic enzymes that degrade cartilage matrix. MSCs home to inflamed joints via systemic circulation and promote tissue regeneration while suppressing chronic inflammation.
Rheumatoid Arthritis
MSC therapy can significantly alleviate symptoms of rheumatoid arthritis, such as joint swelling, pain, and stiffness. Improvements include better joint flexibility and reduced need for immunosuppressive drugs. MSCs work by modulating the overactive immune response, decreasing pro-inflammatory cytokines (like TNF-α and IL-6), promoting regulatory T-cell activation, and directly suppressing autoreactive lymphocytes. Their systemic anti-inflammatory actions help protect joint structures from further damage.
Ankylosing Spondylitis
Patients with ankylosing spondylitis benefit from MSC infusions through decreased spinal stiffness, pain reduction, and improved flexibility. MSCs exert effects by targeting systemic inflammation, secreting anti-inflammatory factors, and modulating Th17/Treg cell balance. Additionally, MSCs reduce fibrosis in spinal ligaments and help maintain vertebral mobility. Their ability to home to sites of inflammation through chemokine signals ensures targeted therapeutic action.
Psoriatic Arthritis
MSC therapy offers relief for psoriatic arthritis, leading to reduced joint pain, improved skin conditions, and better mobility. Mechanistically, MSCs downregulate Th17-driven inflammatory pathways, suppress keratinocyte hyperproliferation, and enhance skin repair via paracrine signaling. By migrating to inflamed tissues, MSCs not only protect joints but also improve skin lesions associated with psoriasis, contributing to an overall improvement in quality of life.
Systemic Lupus Erythematosus (SLE)
In SLE, MSC infusions lead to reduced systemic inflammation, improved skin health, and decreased joint pain. MSCs achieve this by suppressing autoreactive B and T cells, increasing regulatory T cell populations, and reducing production of pathogenic autoantibodies. Through homing to inflamed organs, MSCs stabilize immune activity and promote tissue repair, particularly in kidneys, skin, and joints affected by lupus.

Questions?

+447778936902 (WhatsApp)